These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1144 related articles for article (PubMed ID: 30012210)

  • 1. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
    Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS
    J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
    Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
    PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
    J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)].
    Zhou C; Wang J; Wang B; Cheng Y; Wang Z; Han B; Lu Y; Wu G; Zhang L; Song Y; Zhu B; Hu Y; Wang Z; Song Q; Ren S; He Y; Hu X; Zhang J; Yao Y; Zhao H; Wang Z; Chu Q; Duan J; Liu J; Qin S
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):217-235. PubMed ID: 33896153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
    Cetin B; Bilgetekin İ; Ozet A
    Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapies for Lung Cancer.
    Gubens MA
    J Natl Compr Canc Netw; 2017 May; 15(5S):692-695. PubMed ID: 28515246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
    Hsu JC; Lin JY; Hsu MY; Lin PC
    PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
    Govindan R; Aggarwal C; Antonia SJ; Davies M; Dubinett SM; Ferris A; Forde PM; Garon EB; Goldberg SB; Hassan R; Hellmann MD; Hirsch FR; Johnson ML; Malik S; Morgensztern D; Neal JW; Patel JD; Rimm DL; Sagorsky S; Schwartz LH; Sepesi B; Herbst RS
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors in Lung Cancer and Melanoma.
    Madden K; Kasler MK
    Semin Oncol Nurs; 2019 Oct; 35(5):150932. PubMed ID: 31561846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer.
    Qin A; Street L; Cease K; Viglianti BL; Warren EH; Zhao L; Ramnath N
    Clin Lung Cancer; 2017 Sep; 18(5):559-564. PubMed ID: 28366756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Case of Pseudoprogression During Atezolizumab Therapy 
in Lung Adenocarcinoma].
    Wang X; Zhao Y; Chen Z
    Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):389-394. PubMed ID: 31196374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
    Kamat AM; Bellmunt J; Galsky MD; Konety BR; Lamm DL; Langham D; Lee CT; Milowsky MI; O'Donnell MA; O'Donnell PH; Petrylak DP; Sharma P; Skinner EC; Sonpavde G; Taylor JA; Abraham P; Rosenberg JE
    J Immunother Cancer; 2017 Aug; 5(1):68. PubMed ID: 28807024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
    Chen XY; Yang F
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
    Decatris MP; O'Byrne KJ
    Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.